Anti-Obesity Drugs - Trends & Opportunities Worldwide

News provided by

Jan 29, 2010, 07:32 ET

NEW YORK, Jan. 29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0164264/Anti-Obesity-Drugs---Trends--Opportunities-Worldwide.html

The world today is facing an acute crisis of over-weightiness and its more advance form, obesity. The need to combat obesity may be understood from the fact that it gives rise to life threatening ailments such as heart attack, hypertension, diabetes and certain types of cancer. Obesity prevalence translates to wider opportunities for drug companies, as there exists a huge market for highly efficacious and novel anti-obesity drugs. As such, major proportion of currently available drugs does not meet existing requirements for safety profile and efficacy.

These and other market data and trends are presented in "Anti-Obesity Drugs: Trends & Opportunities Worldwide" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

ANTI-OBESITY DRUGS BMR-1064

CONTENTS

1. METHODOLOGY 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Quantitative Techniques & Reporting Level 3

2. GLOBAL MARKET OVERVIEW AND OUTLOOK 4

Factors Influencing the Market 4

Obesity - A Global Epidemic 4

Trends and Issues 7

Obesity: An Unmet Medical Need 7

Rising Demand for Obesity Therapeutics 7

Barriers to Development of Effective Drugs 7

New Research Aids in Discovery of Novel Drugs 8

Growing Problem of Obesity in Asia Particularly China 8

3. COMPETITION 9

Roche Leads the Race 9

Competition Grows with Pipeline Drugs 10

Current Anti-Obesity Drugs in Pipeline: 2008 11

4. PRODUCT FACTS 11

Diagnosis of Obesity 11

BMI Classification 11

Waist Circumference and BMI 12

Causes of Obesity 12

Select causes of obesity 12

Risks Associated with Obesity 12

Obesity Treatment 13

Review of Available Drugs 14

Phentermine 14

Sibutramine 14

Orlistat 14

Anti-obesity Drugs, Brands and Mechanism of Action 14

5. CORPORATE DEVELOPMENTS 15

Pfizer Halts CP-945, 598 Development 15

Shionogi to Acquire Sciele Pharma 15

Anthill Inks Agreement with Zafgen 15

EMEA Suspends Acomplia 15

GlaxoSmithKline to Sell Alli as OTC Drug 16

Sanofi-Aventis to Market Acomplia in UK 16

Orexigen Receives 4th US Patent for Contrave 16

BELLUS Health to Acquire Innodia 16

Ore Secures License to Develop Romazarit 16

GlaxoSmithKline Receives FDA Approval for Orlistat 17

Pfizer Receives Approval for Slentrol 17

GlaxoSmithKline Secures Licensing Rights of Orlistat 17

Pfizer Collaborates with Bristol-Myers Squibb 17

Takeda Collaborates with LG Life Sciences 18

Takeda to Acquire Paradigm 18

Sanofi-Aventis Secures Reimbursement Status for Acomplia 18

AstraZeneca Inks Agreement with Palatin Technologies 19

Switzerland Includes Acomplia in Reimbursement List 19

Allergan Pockets EndoArt 19

Sanofi-Aventis Receives Approval for Acomplia in Brazil 20

Biocon Inks MoU with Neopharma 20

Aurigene Partners with Forest Laboratories 20

Sanofi-Aventis Receives Swiss Approval for Acomplia 20

Zydus Cadila Introduces Slimona 21

Torrent Introduces Rimoslim 21

Genaera Initiates First Human Trial of Trodusquemine 21

Neurogen Completes First Trial of NGD-4715 21

Alizyme Secures USFDA Approval for Cetilistat Trials 21

GW Pharma to Start Human Trials of New Anti Obesity Drug 22

Epix Completes Phase Ib Trial of PRX-07034 22

7TM Pharma Starts Phase I/II Trial of TM30339 22

6. MAJOR PLAYERS 22

Abbott Laboratories (US) 22

Alizyme Plc (UK) 22

Amylin Pharmaceuticals, Inc. (US) 23

AstraZeneca Plc (UK) 23

F. HOFFMANN-LA ROCHE LTD. (Switzerland) 23

GlaxoSmithKline Plc (UK) 24

Sanofi-Aventis SA (France) 24

SuperGen, Inc. (USA) 24

Takeda Pharmaceutical Company Limited (Japan) 24

VIVUS, Inc. (US) 25

7. GLOBAL MARKET ANALYTICS 25

8. THE UNITED STATES 26

Market Overview 26

Obesity Catching Them Young 27

New Drugs to Rule the Market 27

37 States Experience Increase in Adult Obesity Rate 27

Statistical Data 28

Reimbursement Scenario 29

Regulatory Environment 29

Insufficient Regulatory and Enforcement Laws 30

Obesity and Related Ailments: Burden on Societal and Economic

Cost 30

Competition 30

9. EUROPE 31

a. France 35

b. Germany 36

c. Italy 37

d. The United Kingdom 37

e. Rest of Europe 38

10. REST OF WORLD 39

Brief Review of Select Regions 39

Canada 39

Asia-Pacific 39

Australia 39

China 40

India 40

Drugs Under Development by Indian Companies 41

Japan 41

Korea 41

Use of Diet Pills Lack Proper Monitoring 41

New Zealand 42

EXHIBITS

Table 1: Global Overweight Prevalence (2006): Overweight

Population (%) of Select Countries (BMI ³ 25)

Table 2: Abdominal Obesity Prevalence (%) by Region and Sex

Table 3: Percentage Share Breakdown of Leading Anti-obesity

Drugs Brand Revenues in the World - 2007

Table 4: Obesity Treatment Options and Corresponding Success

Rate

Table 5: Percentage Share Breakdown of Anti-obesity

Prescription Drugs Market by Physician Practices in the

World - 2006

Table 6: Global Anti-Obesity Drugs Market by Region for the

Period 2007-2015 (Sales in US$ Million)

Table 7: Percentage Breakdown of Global Anti-Obesity Drugs

Market by Region for the Years 2009 & 2012

Table 8: Percent Share Breakdown of Leading Weight Loss

Manufacturer Revenues in the US - 2008E

Table 9: US Obesity Rate (2007): Prevalence Rate of Leading

States

Table 10: US Obesity Prevalence Estimates and Forecast

(2008-2020)

Table 11: Percentage Share Breakdown of Anti-obesity

Prescription Drugs Brand Revenues - 2007

Table 12: Anti-Obesity Drugs Market by Segment in the US: